CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Lynparza (olaparib)

Brand Name Lynparza
Generic Name Olaparib
Tumour Type Breast
Indication Treatment of adult patients with deleterious or suspected deleterious germline BRCAmutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
Review Status Not Filed
Manufacturer AstraZeneca Canada
Submission Type Non-Submission
Clarification CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer.
Last Updated March 9, 2020